Last reviewed · How we verify

NCT05116969

A Phase 1 Study of PTX-35 in Healthy Volunteers

Withdrawn Phase 1 Last updated 17 February 2022
What this trial tests

Phase 1 trial testing PTX-35 in Healthy Volunteer. Withdrawn.

Timeline
24 November 2021
Primary endpoint
29 November 2022
29 November 2022

Quick facts

Lead sponsorHeat Biologics
PhasePhase 1
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designsequential
Maskingtriple
Primary purposeother
Start date24 November 2021
Primary completion29 November 2022
Estimated completion29 November 2022

Drugs / interventions tested

Conditions studied

Sponsor

Heat Biologics — full company profile →

Who can join

Adults 18 to 65, any sex, with Healthy Volunteer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Phase 1, Single Dose-Escalation and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous PTX-35 Adminsitration in Healthy Volunteers

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. TNF superfamily control of tissue remodeling and fibrosis.
    Steele H, Cheng J, Willicut A, Dell G, et al · · 2023 · cited 50× · PMID 37465675 · DOI 10.3389/fimmu.2023.1219907

Verify or expand the search:

Other trials of PTX-35

Trials testing the same drug.

Other recruiting trials for Healthy Volunteer

Currently open trials in the same condition.

Other Heat Biologics trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05116969.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing